MHRA orders Class 3 recall of Napralief 250mg batches
→Pharmacy supply teams must quarantine recalled Napralief batches now
Change
UK's MHRA ordered a Class 3 recall of three Napralief 250mg batches (B51496, B51497, B51102) over missing safety and dosage information.
Why it matters
Affected packs omit the maximum-three-tablets-per-day instruction and lack warnings on visual disturbances, allergic reactions and blood-test guidance. Stock must return to suppliers and not be dispensed.
Implications
- → Pharmacy supply teams must immediately stop dispensing the recalled batches — continued supply breaches MHRA recall instructions.
- → Pharmacy inventory teams must immediately quarantine batches B51496, B51497, and B51102 — failure risks accidental patient supply from on-hand stock.
- → Wholesale and pharmacy returns teams must immediately send remaining stock back to suppliers — failure leaves non-compliant stock in the distribution chain.
Full decision brief
See the decision layer
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source
View on OFSI